Godavari Biorefineries Q1 FY27: Chemicals Deliver, Sugar and Ethanol Weigh on Profitability

Godavari Biorefineries Limited opened FY27 with higher revenue but weaker profitability, as strong performance in bio-based chemicals was outweighed by pressure in the integrated sugar, co-generation and ethanol segment. Consolidated total income for Q1 FY27 rose to INR 559.9 crore, up 4.9% year on year, while revenue from operations increased 4.6% to INR 557.9 crore. However, consolidated EBITDA fell to INR 2.6 crore from INR 6.5 crore a year ago, and the company reported a loss after tax of INR 19.3 crore compared with a loss of INR 16.0 crore in Q1 FY26.

Management attributed the margin pressure to elevated inventory carrying costs and higher raw material prices at the consolidated level, even as the bio-based chemicals business benefited from a better product mix and the impact of debottlenecking initiatives completed earlier.

Quarterly performance: higher revenue, lower margins

On a year-on-year basis, consolidated gross profit was broadly stable at INR 100.9 crore versus INR 102.4 crore, but EBITDA margin compressed to 0.5% from 1.2%. Depreciation rose to INR 14.5 crore, and finance costs remained high at INR 13.9 crore, keeping earnings negative for the quarter.

The company’s segment mix also shifted. The investor presentation showed Q1 FY27 revenue mix of 40% from Sugar and Cogeneration, 30% from Bio-Based Chemicals, 28% from Ethanol and 2% unallocated. In Q1 FY26, the mix was 33% Sugar and Cogeneration, 26% Bio-Based Chemicals, 39% Ethanol and 2% unallocated.

Bio-based chemicals: debottlenecking translates into earnings

The bio-based chemicals segment delivered the most tangible operating improvement in the quarter. Segment revenue increased to INR 168.7 crore from INR 141.2 crore in Q1 FY26. Segment EBITDA rose to INR 19.2 crore from INR 12.5 crore, and EBITDA margin expanded to 11.4% from 8.9%.

Management linked this improvement to debottlenecking initiatives completed in FY26, which are now translating into higher sales and better operating efficiencies. On the earnings call, management also indicated an expectation of around INR 190 crore of bio-based chemicals sales in the coming quarter, suggesting continued momentum.

To support growth, the company stated it has decided to invest about INR 25 crore in further debottlenecking of capacity for its bio-based specialty chemical business. Management commentary also noted that incremental growth in this segment is expected to come from bio-based specialty chemicals.

In addition to operating performance, the company highlighted an Indian patent for a cost-effective process to manufacture branched alcohols, strengthening its intellectual property portfolio.

Sugar, co-gen and ethanol: operational pressure and the case for optionality

The integrated sugar, cogeneration and ethanol segment remained the key drag on consolidated profitability. Segment revenue came in at INR 377.9 crore, marginally lower than INR 382.8 crore in Q1 FY26. Segment EBITDA loss widened to INR 14.6 crore from INR 4.5 crore.

Management attributed the weaker performance to challenging feedstock conditions and higher manufacturing costs, along with pressure from ethanol tender allotments. At the same time, it pointed to improved sugar realizations as a potential tailwind going forward.

A key operational milestone during the quarter was the commissioning of a 200 KLPD grain-based distillery at Sameerwadi, taking total distillery capacity to 800 KLPD. The investor presentation described this as a dual-feedstock facility capable of processing corn and grain alongside existing sugarcane juice operations. The company also stated this adds 60 million litres of annual ethanol capacity.

The larger strategic point management emphasized was flexibility. With sugar prices improving and sugarcane juice ethanol prices described as having remained stable over multiple years, the company said it continues to evaluate diversion economics between sugar and ethanol.

To enhance fungibility further, management said it is evaluating the addition of 160 KLPD capacity within the existing 800 KLPD cap. The stated rationale is that if sugar economics lead to higher diversion of sugarcane juice to sugar, fermentation and distillation capacity may become available, and a front-end grain preparation addition could help use that capacity for grain-to-ethanol conversion.

Climate risk remained an explicit area of focus. Management discussed monitoring rainfall and dam levels in its operating regions, and said that in the last few weeks prior to the call, rainfall and dam levels had improved relative to earlier concerns.

Innovation pipeline: DME, bio-butanol and drug discovery milestones

The company’s investor communication positioned the energy transition and global supply tightness as structural tailwinds for bio-based chemicals and ethanol. On the call, management discussed early-stage clean fuel projects and provided timelines where available.

For DME (dimethyl ether), management stated pilot trials are progressing as planned, with conclusions expected by March 2027. It also discussed DME as an LPG substitute in the context of energy transition opportunities.

For bio-butanol, management said it has secured an MoU with Synthomer for bio-butanol as a chemical intermediate, and is seeking additional customers. It also noted ongoing engagement with Indian government initiatives exploring butanol pathways for fuels.

Drug discovery was another highlight, with the investor presentation noting a Japanese patent grant for a novel anti-cancer molecule and a CDSCO filing for preliminary efficacy trials. Management stated that safety trials have been completed and the company has applied to CDSCO for approval to begin preliminary efficacy trials, with a target to start trials by Q3 FY27 subject to approvals. It also stated the estimated spend to reach preliminary efficacy is about INR 20 crore over the next two to three years, and that it does not expect fund-raising for this phase.

What to watch from here

Godavari Biorefineries is entering FY27 with a clearer split in operating momentum. Bio-based chemicals is delivering measurable margin improvement and is being supported by incremental capex, while sugar and ethanol profitability remains sensitive to feedstock conditions, manufacturing costs, tendering dynamics and the sugar versus ethanol diversion decision.

Near-term monitoring points include whether the bio-based chemicals sales trajectory toward the stated INR 190 crore quarterly run-rate sustains, and whether the integrated segment sees relief from improved sugar realizations and better utilization supported by the new grain distillery. Longer-dated catalysts are the DME pilot trial outcomes expected by March 2027 and regulatory progression on the oncology molecule’s preliminary efficacy trials targeted to begin in Q3 FY27 subject to approvals.